Price
No data yet.
Social Signal Score
Analyst Ratings
17 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jacqueline E. Shea
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 112
- Beta
- 1.63
- Country
- US
- Piotroski score
- 0 / 9 (Weak)
- Altman Z-score
- -55.62
Financials
Revenue
$0.00-100.0%Net Income
$-6.01MEBITDA
$-5.69MFree Cash Flow
$-18.05MEPS (diluted)
$-0.07Shares Outstanding (diluted)
81.62M+1227.3%Operating Expenses
$18.62MCash & Debt
$36.67MReturn of Capital
$0.00Revenue by Segment (annual)
$65.3KDividend per Share
$0.07Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $65.3K | $-84.95M | $-1.81 |
| 2024 | $217.8K | $-107.25M | $-3.95 |
| 2023 | $832.0K | $-135.12M | $-6.09 |
| 2022 | $10.26M | $-279.82M | $-14.07 |
| 2021 | $1.77M | $-303.66M | $-1.42 |
| 2020 | $7.41M | $-166.41M | $-1.07 |
| 2019 | $4.11M | $-119.36M | $-0.97 |
| 2018 | $30.48M | $-96.97M | $-1.05 |
| 2017 | $42.22M | $-88.21M | $-1.08 |
| 2016 | $35.37M | $-73.74M | $-1.01 |
| 2015 | $40.57M | $-29.19M | $-0.43 |
| 2014 | $10.46M | $-36.12M | $-0.61 |
| 2013 | $13.47M | $-66.03M | $-1.43 |
| 2012 | $4.12M | $-19.67M | $-0.58 |
Valuation
INOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-42.86%Social Signal Score
Mentions (8)
- Newsseekingalpha.com·24d ago·Neutral
Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
View source ↗ - Newsmarketbeat.com·25d ago·Negative
Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms Inovio Pharmaceuticals NASDAQ: INO said its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, or RRP, remains under U.S. Food and Drug Administration review, with a target action date of Oct. 30.
View source ↗ - Newsmarketbeat.com·26d ago·Neutral
Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP Inovio Pharmaceuticals NASDAQ: INO is approaching an October 30 PDUFA date for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis, or RRP, President and CEO Jacky Shea said during a Cantor Fitzgerald fireside chat.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·34d ago·Neutral
INOVIO to Participate in Upcoming Investor Conferences PLYMOUTH MEETING, Pa., Sept. 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following investor conferences: Cantor Global Healthcare Conference (New York) Date: Wednesday, September 9 Fireside Chat: 3:20 PM ET Webcast: https://…
View source ↗ - Newsmarketbeat.com·54d ago·Negative
Inovio Pharmaceuticals Q2 Earnings Call Highlights Inovio Pharmaceuticals NASDAQ: INO said the U.S. Food and Drug Administration has completed several key steps in its review of the company's biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis, or RRP, while the company continues preparations for a potential commercial launch.
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Inovio Pharmaceuticals, Inc. (INO) Q2 2026 Earnings Call Transcript Inovio Pharmaceuticals, Inc. (INO) Q2 2026 Earnings Call Transcript
View source ↗ - Newsprnewswire.com·54d ago·Negative
INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026 Commercial preparations advancing in anticipation of potential product launch for INO-3107 Positive topline results reported from Phase 3 trial for VGX-3100 for the tr
View source ↗
Earnings
Tue, Nov 10(in 5 weeks)
Consensus estimate $-0.20 per share
Typical surprise +20.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.07 vs $-0.22beat
- Wed, May 13$-0.28 vs $-0.35beat
- Thu, Mar 12$0.06 vs $-0.37beat
- Mon, Nov 10$-0.87 vs $-0.42miss
- Tue, Aug 12$-0.61 vs $-0.63beat
- Tue, May 13$-0.51 vs $-0.74beat
Estimates and results for INO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by INO officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Chris Jacobshouse · NY27 · disclosed Nov 6, 2020 (59d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.